Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Haematological cancer

Bortezomib in MCL—new standard of care or just another option?

Nature Reviews Clinical Oncology volume 12, pages 376–378 (2015)Cite this article

Subjects

In a recent international phase III trial, addition of bortezomib to a R-CHOP-like immunochemotherapy regimen for the first-line treatment of mantle-cell lymphoma resulted in a clinically meaningful extension of median progression-free survival. This finding emphasizes the role of targeted therapies in a relatively chemotherapy-refractory disease; however, therapeutic recommendations have to consider the observed haematotoxicity of this combination.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Swerdlow, S. H. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th edn (WHO Press, 2008).

    Google Scholar 

  2. Dreyling, M. et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25 (Suppl. 3), iii83–iii92 (2014).

    Article  Google Scholar 

  3. Robak, T. et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N. Engl. J. Med. 372, 944–953 (2015).

    Article  CAS  Google Scholar 

  4. Manni, S. et al. Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells. PLoS ONE 8, e75280 (2013).

    Article  CAS  Google Scholar 

  5. Goy, A. et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann. Oncol. 20, 520–525 (2009).

    Article  CAS  Google Scholar 

  6. Till, B. G. et al. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for previously untreated mantle cell lymphoma: SWOG 0601 [abstract]. Blood 124, a149 (2014).

    Google Scholar 

  7. Richardson, P. G., Laubach, J. P., Munshi, N. C. & Anderson, K. C. Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematology Am. Soc. Hematol. Educ. Program 2014, 255–261 (2014).

    Article  Google Scholar 

  8. Hermine, O. et al. Alternating courses of 3× CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net) [abstract]. Blood 120, a151 (2012).

    Google Scholar 

  9. Drach, J. et al. Efficacy and safety of frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in a subset of newly diagnosed mantle cell lymphoma (MCL) patients (pts) medically eligible for transplantation in the randomized phase 3 LYM-3002 study (NCT00722137) [abstract]. Blood 124, a3061 (2014).

    Google Scholar 

  10. Coiffier, B. et al. Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib–rituximab versus rituximab. Clin. Cancer Res. 19, 2551–2561 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine III, University Hospital, Ludwig-Maximilians University, Marchioninistrasse 15, 81377, Munich, Germany

    Martin Dreyling

Authors
  1. Martin Dreyling
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Martin Dreyling.

Ethics declarations

Competing interests

M.D. declares institutional support of clinical trials by Celgene, Janssen, Pfizer, Roche. M.D. has served on the scientific advisory boards of Celgene and Janssen, and has received speakers' honouraria from Celgene, Janssen, Mundipharma, Pfizer, and Roche.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dreyling, M. Bortezomib in MCL—new standard of care or just another option?. Nat Rev Clin Oncol 12, 376–378 (2015). https://doi.org/10.1038/nrclinonc.2015.101

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2015.101

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing